(Q412323)

English

rituximab

pharmaceutical drug

IDEC-102
RG-105
IDEC-C2B8
AntiCD20
R-105 IDEC-102
Ig gamma-1 chain C region
Rituxan
Mabthera

In more languages

default for all languages

No label defined

No description defined

Statements

type of chemical entity

0 references

chemical compound

0 references

1 reference

Rituximab (English)

language of work or name

publication date

17 November 2015

image of molecular model or crystal lattice model

Rituximab.png
1,020 × 625; 262 KB

0 references

active ingredient in

1 reference

European Medicines Agency product number

EMEA/H/C/000165

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000165/human_med_000897.jsp

22 March 2017

medical condition treated

B-cell lymphoma

2 references

language of work or name

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

hairy cell leukemia

1 reference

Drug Indications Extracted from FAERS

2 October 2018

granulomatosis with polyangiitis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

chronic lymphocytic leukemia

1 reference

Drug Indications Extracted from FAERS

2 October 2018

nephrotic syndrome

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

post-transplant lymphoproliferative disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

diffuse large B-cell lymphoma

1 reference

Drug Indications Extracted from FAERS

2 October 2018

lupus nephritis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

interstitial lung disease

1 reference

Drug Indications Extracted from FAERS

2 October 2018

Waldenström macroglobulinemia

1 reference

Drug Indications Extracted from FAERS

2 October 2018

thrombotic thrombocytopenic purpura

1 reference

Drug Indications Extracted from FAERS

2 October 2018

graft-versus-host disease

1 reference

Drug Indications Extracted from FAERS

2 October 2018

microscopic polyangiitis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

cryoglobulinemia

1 reference

Drug Indications Extracted from FAERS

2 October 2018

non-Hodgkin lymphoma

1 reference

Drug Indications Extracted from FAERS

2 October 2018

myasthenia gravis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

neuromyelitis optica

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

thrombocytopenia

1 reference

Drug Indications Extracted from FAERS

2 October 2018

Sjögren's syndrome

1 reference

Drug Indications Extracted from FAERS

2 October 2018

membranous glomerulonephritis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

central nervous system lymphoma

1 reference

Drug Indications Extracted from FAERS

2 October 2018

mantle cell lymphoma

1 reference

Drug Indications Extracted from FAERS

2 October 2018

autoimmune hemolytic anemia

1 reference

Drug Indications Extracted from FAERS

2 October 2018

bullous pemphigoid

1 reference

Drug Indications Extracted from FAERS

2 October 2018

multiple sclerosis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

Castleman's disease

1 reference

Drug Indications Extracted from FAERS

2 October 2018

AntiMOG associated encephalomyelitis

0 references

legal status (medicine)

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category A

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Rituximab

18 June 2018

1 reference

https://www.pfizer.com/products/product-list

has characteristic

biopharmaceutical

1 reference

Rituximab (English)

language of work or name

publication date

17 November 2015

subject has role

immunologic factor

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

disease-modifying antirheumatic drug

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

immunological antineoplastic agent

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

essential medicine

0 references

monoclonal antibody

1 reference

language of work or name

Rituximab (English)

publication date

17 November 2015

riTUXimab

has characteristic

Tall Man lettering

Institute for Safe Medication Practices

1 reference

https://www.ismp.org/recommendations/tall-man-letters-list

2 September 2022

0 references

Commons category

Rituximab

0 references

Identifiers

987007554340605171

1 reference

National Library of Israel Names and Subjects Authority File

subject named as

rituximab

0 references

CAS Registry Number

2 references

Rituximab (English)

publication date

17 November 2015

Rituximab (English)

24 April 2016

http://chem.sis.nlm.nih.gov/chemidplus/rn/174722-31-7

1 reference

language of work or name

Rituximab (English)

19 January 2016

1 reference

Hazardous Substances Data Bank

publication date

28 October 2019

RITUXIMAB (English)

10 May 2021

DSSTox substance ID

0 references

0 references

695-706-4

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal IDEC-C2B8 .gamma.1-chain), disulfide with human-mouse monoclonal IDEC-C2B8 .kappa.-chain, dimer (English)

CAS no.: 174722-31-7 (English)

ECHA Substance Infocard ID

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal IDEC-C2B8 .gamma.1-chain), disulfide with human-mouse monoclonal IDEC-C2B8 .kappa.-chain, dimer (English)

CAS no.: 174722-31-7 (English)

1 reference

language of work or name

Rituximab (English)

publication date

17 November 2015

Guide to Pharmacology Ligand ID

0 references

MeSH descriptor ID

subject named as

Rituximab

0 references

D12.776.124.486.485.114.224.075.785

0 references

D12.776.124.790.651.114.224.075.785

0 references

D12.776.377.715.548.114.224.284.785

0 references

1 reference

26 February 2018

0 references

2 references

RITUXIMAB (English)

19 January 2016

Rituximab (English)

24 April 2016

http://chem.sis.nlm.nih.gov/chemidplus/rn/174722-31-7

MedlinePlus drug identifier

0 references

1 reference

language of work or name

RITUXIMAB (English)

19 January 2016

1 reference

imported from Wikimedia project

English Wikipedia

0 references

electronic Essential Medicines List medicine ID

0 references

Encyclopedia of China (Third Edition) ID

subject named as

利妥昔单抗

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

Microsoft Academic ID

0 references

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

1 reference

UK Parliament thesaurus ID

subject named as

Rituximab

0 references

WikiProjectMed ID

0 references

WikiSkripta article ID

0 references

Sitelinks

Wikipedia(34 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Rituximab

Retrieved from "https://www.wikidata.org/w/index.php?title=Q412323&oldid=2256003206"

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.

Alternative Proxies:

Alternative Proxy